# VLS-1488

Source: https://onco.cc/drugs/vls-1488/  
OnCo record `vls-1488` (Treatment). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

VLS-1488 is an experimental pill from Volastra Therapeutics, in phase 1 trials for high-grade serous ovarian cancer and other cancers with unstable chromosomes.

## Summary

VLS-1488 is a small molecule, oral from Volastra Therapeutics. Blocks KIF18A, a motor protein that cancer cells with unstable chromosomes depend on to divide. Its phase 1/2 study (NCT05902988) recruits people with high-grade serous ovarian cancer, squamous non-small cell lung cancer, triple-negative breast cancer, head and neck squamous cell carcinoma and uterine cancers. The company reports an FDA Fast Track designation in platinum-resistant high-grade serous ovarian cancer. Whether it works in people has not been established.

## Fields

- Kind: Treatment
- Status: phase-1
- Last checked: 2026-11-04
- Tags: pipeline; ctgov-ingest
- Code: VLS-1488
- Modality: Small molecule, oral
- Mechanism: Blocks KIF18A, a motor protein that cancer cells with unstable chromosomes depend on to divide.

## Sources

- Volastra Therapeutics pipeline: https://www.volastratx.com/pipeline/
- ClinicalTrials.gov NCT05902988: https://clinicaltrials.gov/study/NCT05902988

## Connected records

- cancers: [Head and neck squamous cell carcinoma](https://onco.cc/cancers/head-and-neck/), [High-grade serous ovarian cancer](https://onco.cc/cancers/high-grade-serous-ovarian-cancer/), [Triple-negative breast cancer (TNBC)](https://onco.cc/cancers/tnbc/)
- targets: [KIF18A](https://onco.cc/targets/kif18a/)
- companies: [Volastra Therapeutics](https://onco.cc/companies/volastra-therapeutics/)
- trials: [A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer](https://onco.cc/trials/nct05902988/)

---
JSON: https://onco.cc/api/v1/entities/vls-1488.json